Skip to content

Evaluation of the Efficacy and Safety of Dexmedetomidine Nasal Spray for Preoperative Sedation in Children

Evaluation of the Efficacy and Safety of Dexmedetomidine Nasal Spray for Preoperative Sedation in Children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123634
Enrollment
Unknown
Registered
2026-04-28
Start date
2026-04-28
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery for Pediatric Patients

Interventions

Dexmedetomidine Nasal Spray Group (Experimental group) :Dexmedetomidine nasal spray. Intranasal administration was based on body weight (one puff for 10.7kg<= body weight <19.4kg and two sprays for 19
Normal Saline Group (Control group):Saline nasal spray identical in appearance. The administration method, timing, and number of sprays are identical to those in the experimental group.

Sponsors

Shaoxing People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1. Children aged between 2 and 6 years old who are scheduled to undergo various surgeries under general anesthesia, such as pediatric general surgery (e.g., inguinal hernia repair, appendectomy, etc.), pediatric urology surgery (e.g., circumcision, cryptorchidism descent fixation, etc.), and pediatric otolaryngology surgery (e.g., adenoidectomy, tonsillectomy, etc.); 2. American Society of Anesthesiologists (ASA) classification of grades I - II; 3. Body mass index ranging from 10.7 to 28 kg/m^2; 4. The parents of the children sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. There are underlying diseases that may affect the research results, such as severe cardiopulmonary dysfunction, liver and kidney dysfunction, and neurological disorders; 2. Allergic to dexmedetomidine or other related drugs; 3. Had a history of upper respiratory tract infection within the recent 1 week before the surgery; 4. Abnormal nasal anatomy or nasal diseases (such as deviation of the nasal septum, sinusitis, etc.) that affect drug absorption; 5. History of drug abuse or mental illness.

Design outcomes

Primary

MeasureTime frame
preoperative modified Ramsay Sedation Scale (RSS) score;

Secondary

MeasureTime frame
Frankl Behavior Rating Scale score;Parental Separation Anxiety Scale (PSAS) score;modified Yale Preoperative Anxiety Scale (m-YPAS) score;assessment of mask acceptance;Induction Compliance Checklist (ICC) score;perioperative adverse reactions;perioperative medication profile;perioperative vital signs;Surgeon's Satisfaction Score with the Procedure;Time to Emergence (from discontinuation of the drug to the child opening eyes on command);Length of Stay in the PACU;Time to Extubation;PAED Scale (Pediatric Anesthesia Emergence Delirium Scale);FLACC Scale (Face, Legs, Activity, Cry, Consolability Scale);

Countries

China

Contacts

Public ContactChen Zhonghua

Shaoxing People's Hospital

chenbeijing116@163.com+86 136 2575 1526

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026